![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 08, 2013 1:05:26 PM
Feds launch probe of AstraZeneca's controversial late-stage Brilinta study
October 31, 2013 | By John Carroll
When EP Vantage went back to look over some of the bullish peak sales projections made for a new generation of medicines, its analysts pulled out AstraZeneca's blood-thinner Brilinta as one of the industry's top duds. Once expected to crest at $2.52 billion a year, most analysts now don't see it hitting the $1 billion blockbuster mark, with a poor impact in the U.S. market dragging down projections.
Now AstraZeneca ($AZN) has another Brilinta headache to deal with. In its third-quarter earnings release the company revealed that the U.S. Justice Department's civil division is probing PLATO, its big clinical trial of Brilinta. The feds demanded "documents and information" on the study. And the pharma giant noted briefly that it will be cooperating with investigators.
While the company offers no details about exactly what the feds are after, the PLATO study has been subjected to some harsh criticism from James DiNicolantonio, Pharm.D., and Dr. Ales Tomek, of Charles University in Prague. The two raised serious questions about the study results last summer in a report published in the International Journal of Cardiology. They highlighted concerns that study results reviewed by an independent CRO demonstrated a worse outcome for the drug--ticagrelor--than the clopidogrel arm compared to the positive results reported by AstraZeneca's investigators.
They also reported that almost half of the favorable results for Brilinta were drawn from just two Eastern European countries, Hungary and Poland. Reporting on cardiovascular events appeared to favor Brilinta and "an estimated 23 definite or possible cardiovascular events or deaths on ticagrelor (Brilinta) were either not submitted for adjudication, inactivated, deleted or were downgraded to 'softer' endpoints (this was not shown in the FDA review for clopidogrel), and four FDA reviewers voted for non-approval of ticagrelor."
"The FDA report highlights what appear to be multiple serious deficiencies in the reporting of the PLATO results, which clinicians will not have gleaned from the primary publication alone," they wrote, according to a report in MedPage Today. "Individual clinicians may therefore wish to carefully reconsider their practice of ticagrelor prescription for this indication. Guideline bodies should also evaluate the information in its totality."
Oh, and now the EMA is after them too:
EU watchdogs demand info on AstraZeneca's disputed Brilinta trial November 8, 2013 | By Tracy Staton
Last week, AstraZeneca ($AZN) succinctly disclosed that Department of Justice investigators are digging into its data on the blood thinner Brilinta. Now, European regulators are adding their shovels to the effort. If they're not satisfied with their findings, AstraZeneca's hopes for pumping up Brilinta sales could be in vain.
At issue is the PLATO trial, a pivotal study that helped lay the foundation for Brilinta's regulatory approval. The head-to-head trial against megablockbuster clot-fighter Plavix helped support a superiority claim on Brilinta's FDA label when its was approved in 2011. That gave AstraZeneca some extra marketing ammo. And that was important, given the fact that the Sanofi ($SNY) and Bristol-Myers Squibb ($BMY) drug--the standard of care--was about to go off patent. The study also gave AstraZeneca some pricing support; in setting a premium price for the drug in Europe, the company cited PLATO data as justification.
But how justified was it, really? The European Medicines Agency (EMA) said yesterday that it asked AstraZeneca for more information after the Justice Department's probe came to light. "The EMA takes seriously any information that may have an impact on the profile of a drug's benefits and risks," an EMA spokeswoman told Reuters. "At the moment we are at the point of trying to understand what is going on."
PLATO has come under fire before. Researchers have pointed to flaws in the study, with some suggesting that the data appeared to be fudged to benefit Brilinta. Last summer, a report in the International Journal of Cardiology said an independent group's review of PLATO data yielded a more negative picture than AstraZeneca's analysis.
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM